8-K Announcements
6Material company update
Apr 23, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Mar 10, 2026·SEC
Zura Bio Limited(ZURA)Earnings, Financials & Key Ratios
ZURA•NASDAQ
$4.89
$318M mkt cap·Price updated May 6, 2026
AboutZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.Show more
- Revenue$0
- EBITDA-$75M-36.4%
- Net Income-$99M-89.6%
- EPS (Diluted)-1.06-76.7%
- ROE-75.97%-73.7%
ZURA Key Insights
Zura Bio Limited (ZURA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 85 (top 15%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 25.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ZURA Price & Volume
Zura Bio Limited (ZURA) stock price & volume — 10-year historical chart
Loading chart...
ZURA Growth Metrics
Zura Bio Limited (ZURA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-107.74%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-94.67%
Return on Capital
10 Years-64.45%
5 Years-64.45%
3 Years-93.3%
Last Year-57.54%
ZURA Recent Earnings
Zura Bio Limited (ZURA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
Mar 19, 2026EPS
$0.49
Est $0.18
-172.2%
Revenue
—
Q4 2025
Nov 13, 2025EPS
$0.21
Est $0.19
-10.5%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.17
Est $0.19
+10.5%
Revenue
—
Q2 2025
May 8, 2025EPS
$0.19
Est $0.17
-11.8%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 19, 2026 | $0.49vs $0.18-172.2% | — |
| Q4 2025 | Nov 13, 2025 | $0.21vs $0.19-10.5% | — |
| Q3 2025 | Aug 14, 2025 | $0.17vs $0.19+10.5% | — |
| Q2 2025 | May 8, 2025 | $0.19vs $0.17-11.8% | — |
Based on last 12 quarters of dataView full earnings history →
ZURA Peer Comparison
Zura Bio Limited (ZURA) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 ARQT | 2.98B | 24.17 | -185.92 | 91.34% | -4.29% | -8.52% | 0.03 | |
 DAWN | 2.22B | 21.53 | -20.70 | 20.6% | -67.85% | -23.43% | 0.01 | |
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | 4.91% | |
 LLY | 932.64B | 987.11 | 43.01 | 44.7% | 34.98% | 101.17% | 0.96% | 1.60 |
Compare ZURA vs Peers
Zura Bio Limited (ZURA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZURA Income Statement
Zura Bio Limited (ZURA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 49K |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -49K▲ 0% |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 1.09M | 27.16M | 62.64M | 55.19M | 75.25M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 1.09M | 3.47M | 18.64M | 30.79M | 33.16M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 0 | 23.69M | 44M | 24.4M | 42.08M |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.09M▲ 0% | -27.16M▼ 2387.4% | -62.64M▼ 130.6% | -55.19M▲ 11.9% | -75.25M▼ 36.3% |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | -2387.39% | -130.61% | 11.89% | -36.34% |
| EBITDA | 8.42M | -27.16M | -62.64M | -55.18M | -75.25M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | - | -422.72% | -130.61% | 11.91% | -36.36% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 9K | 0 |
| EBIT | 8.42M | -27.16M | -62.64M | -55.19M | -75.25M |
| Net Interest Income | 23.48K | 570 | 2.19M | 8M | 6.34M |
| Interest Income | 23.48K | 570 | 2.19M | 8M | 6.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 9.51M | -171K | 2.08M | 2.79M | 6.6M |
| Pretax Income | 8.42M▲ 0% | -27.33M▼ 424.7% | -60.56M▼ 121.6% | -52.4M▲ 13.5% | -68.65M▼ 31.0% |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | 8.42M▲ 0% | -25.74M▼ 405.8% | -60.36M▼ 134.5% | -52.4M▲ 13.2% | -99.35M▼ 89.6% |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | - | -405.8% | -134.52% | 13.18% | -89.59% |
| Net Income (Continuing) | 8.42M | -27.33M | -60.56M | -52.4M | -68.65M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 10M | 20.22M | 13.2M | 0 |
| EPS (Diluted) | 0.40▲ 0% | 0.21▼ 47.5% | -2.09▼ 1095.2% | -0.60▲ 71.3% | -1.06▼ 76.7% |
| EPS Growth % | - | -47.5% | -1095.24% | 71.29% | -76.67% |
| EPS (Basic) | 0.40 | 0.21 | -2.09 | -0.60 | -1.06 |
| Diluted Shares Outstanding | 17.25M | 17.25M | 33.06M | 75.07M | 94.16M |
| Basic Shares Outstanding | 17.25M | 17.25M | 33.06M | 75.07M | 94.16M |
| Dividend Payout Ratio | - | - | - | - | - |
ZURA Balance Sheet
Zura Bio Limited (ZURA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Total Current Assets | 1.15M | 1.78M | 100.84M | 178.74M | 112.31M |
| Cash & Short-Term Investments | 729.22K | 1.57M | 99.81M | 176.5M | 109.41M |
| Cash Only | 729.22K | 1.57M | 99.81M | 176.5M | 109.41M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 0 | 189.3K | 1.04M | 2.25M | 2.9M |
| Total Non-Current Assets | 139.4M | 3.49M | 0 | 789K | 1.64M |
| Property, Plant & Equipment | 0 | 0 | 0 | 91K | 126K |
| Fixed Asset Turnover | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 139.4M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 3.49M | 0 | 698K | 1.51M |
| Total Assets | 140.55M▲ 0% | 5.26M▼ 96.3% | 100.84M▲ 1816.4% | 179.53M▲ 78.0% | 113.95M▼ 36.5% |
| Asset Turnover | - | - | - | - | - |
| Asset Growth % | - | -96.26% | 1816.44% | 78.03% | -36.53% |
| Total Current Liabilities | 272.29K | 14.82M | 20.3M | 19.51M | 12.41M |
| Accounts Payable | 0 | 2.01M | 2.75M | 733K | 0 |
| Days Payables Outstanding | - | - | - | - | - |
| Short-Term Debt | 0 | 7.76M | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 272.29K | 2.77M | 1.2M | 18.78M | 12.41M |
| Current Ratio | 4.23x | 0.12x | 4.97x | 9.16x | 9.05x |
| Quick Ratio | 4.23x | 0.12x | 4.97x | 9.16x | 9.05x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 10.08M | 12.5M | 990K | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 10.08M | 12.5M | 990K | 0 | 0 |
| Total Liabilities | 10.35M | 27.32M | 21.29M | 19.51M | 12.41M |
| Total Debt | 0 | 7.76M | 0 | 0 | 0 |
| Net Debt | -729.22K | 6.19M | -99.81M | -176.5M | -109.41M |
| Debt / Equity | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | -0.09x | - | - | - | - |
| Interest Coverage | - | - | - | - | - |
| Total Equity | 130.2M▲ 0% | -22.06M▼ 116.9% | 79.55M▲ 460.7% | 160.02M▲ 101.2% | 101.54M▼ 36.5% |
| Equity Growth % | - | -116.94% | 460.68% | 101.15% | -36.55% |
| Book Value per Share | 7.55 | -1.28 | 2.41 | 2.13 | 1.08 |
| Total Shareholders' Equity | 130.2M | -32.06M | 59.33M | 146.81M | 101.54M |
| Common Stock | 139.38M | 0 | 4K | 7K | 7K |
| Retained Earnings | -9.18M | -32.06M | -103.49M | -155.9M | -224.55M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 10M | 20.22M | 13.2M | 0 |
ZURA Cash Flow Statement
Zura Bio Limited (ZURA) cash flow — operating, investing & free cash flow history
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Cash from Operations | -1.1M | -1.2M | -15.05M | -28.08M | -64.81M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | - | -9.46% | -1152.41% | -86.5% | -130.86% |
| Net Income | 8.42M | -27.33M | -60.56M | -52.4M | -68.65M |
| Depreciation & Amortization | 0 | 0 | 0 | 9K | 49K |
| Stock-Based Compensation | 0 | 334K | 9.65M | 16.8M | 12.33M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -9.28M | 22.26M | 30.74M | 5.21M | -4.91M |
| Working Capital Changes | -235.6K | 3.54M | 5.12M | 2.31M | -3.63M |
| Change in Receivables | 2.87K | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 288.29K | 0 | 4.21M | -2.16M |
| Cash from Investing | -139.38M | -12M | -8M | -5.08M | -113K |
| Capital Expenditures | 0 | -12M | -8M | -75K | -113K |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -5M | 0 |
| Cash from Financing | 141.21M | 14.77M | 121.29M | 109.84M | -2.16M |
| Debt Issued (Net) | -117.38K | 7.6M | -10M | 0 | 0 |
| Equity Issued (Net) | 140.82M | 10M | 116.41M | 60.76M | 5.2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 505K | -2.83M | 14.89M | 49.09M | -7.37M |
| Net Change in Cash | 729.22K▲ 0% | 1.57M▲ 114.9% | 98.24M▲ 6169.2% | 76.69M▼ 21.9% | -67.09M▼ 187.5% |
| Free Cash Flow | -1.1M▲ 0% | -13.2M▼ 1102.2% | -23.05M▼ 74.6% | -28.15M▼ 22.1% | -64.93M▼ 130.6% |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | - | -1102.2% | -74.63% | -22.11% | -130.64% |
| FCF per Share | -0.06 | -0.77 | -0.70 | -0.37 | -0.69 |
| FCF Conversion (FCF/Net Income) | -0.13x | 0.05x | 0.25x | 0.54x | 0.65x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
ZURA Key Ratios
Zura Bio Limited (ZURA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | 6.46% | -47.6% | -209.97% | -43.75% | -75.97% |
| Return on Invested Capital (ROIC) | - | -35.86% | - | - | - |
| FCF Conversion | -0.13x | 0.05x | 0.25x | 0.54x | 0.65x |
ZURA SEC Filings & Documents
Zura Bio Limited (ZURA) SEC filings — annual & quarterly reports (10-K, 10-Q)
ZURA Frequently Asked Questions
Zura Bio Limited (ZURA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Zura Bio Limited (ZURA) grew revenue by 0.0% over the past year. Growth has been modest.
Zura Bio Limited (ZURA) reported a net loss of $99.4M for fiscal year 2025.
Dividend & Returns
Zura Bio Limited (ZURA) has a return on equity (ROE) of -76.0%. Negative ROE indicates the company is unprofitable.
Zura Bio Limited (ZURA) had negative free cash flow of $64.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More ZURA
Zura Bio Limited (ZURA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates